Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.
Saved in:
| Title: | Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. |
|---|---|
| Authors: | Machiels JP; Department of Medical Oncology, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique (Pole MIRO), UCLouvain, Brussels, Belgium., Tao Y; Department of Radiation Oncology, Gustave Roussy, Villejuif, France., Licitra L; Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy., Burtness B; Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States., Tahara M; Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Rischin D; Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, VIC, Australia., Alves GV; Medical Oncology, Centro Integrado de Pesquisa em Oncología, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil., Lima IPF; Department of Oncology, CRIO Centro Regional Integrado de Oncología, Fortaleza, Brazil., Hughes BGM; Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, QLD, Australia., Pointreau Y; Department of Radiation Oncology, Centre Jean Bernard Institut Inter-régionaL de Cancérologie, Centre de Cancérologie de la Sarthe, Le Mans, France., Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Türkiye., Laban S; Head & Neck Cancer Center of the Comprehensive Cancer Center Ulm, Ulm University Medical Center, Ulm, Germany., Greil R; Department of Internal Medicine, Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria., Burian M; Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria., Hetnal M; Andrzej Frycz Modrzewski Krakow University, Amethyst Radiotherapy Center, Rydygier Hospital, Krakow, Poland., Delord JP; European Cancer Organisation, Brussels, Belgium., Mesia R; Medical Oncology Department, Catalan Institute of Oncology - Badalona, B-ARGO group, CARE program, IGTP, Badalona, Spain., Taberna M; Savana, Madrid, Spain., Waldron J; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Simon C; Department of Otolaryngology-Head and Neck Surgery, University Medical Center Vaud (CHUV) - Lausanne University Hospital, Lausanne, Switzerland., Gregoire V; Radiation Oncology Department, Léon Bérard Cancer Center, Lyon, France., Harrington K; The Institute of Cancer Research, London, United Kingdom., Black CM; Merck & Co., Inc., Rahway, NJ, United States., Norquist JM; Merck & Co., Inc., Rahway, NJ, United States., Wang A; Merck & Co., Inc., Rahway, NJ, United States., Gumuscu B; Merck & Co., Inc., Rahway, NJ, United States., Bidadi B; Merck & Co., Inc., Rahway, NJ, United States., Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Oct 06; Vol. 15, pp. 1645509. Date of Electronic Publication: 2025 Oct 06 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
